RxDoctor Payments Data

Carlene Springer, APRN

Family · Hastings, NENPI 1669875803

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,028 of the $11,859 with a category attached, or 84.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,859in general payments, 2019–2025

Across 604 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$979
  • Eisai Inc.$956
  • Seagen Inc.$686
  • Pfizer$620
  • Merck$596
  • Daiichi Sankyo Inc.$584
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$5435%
  • Food & beverage$10,02885%
  • Education$1,28811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis54$979
Eisai Inc.24$956
Seagen Inc.26$686
Pfizer36$620
Merck33$596
Daiichi Sankyo Inc.38$584
AstraZeneca(2 entities)24$472
Lilly USA, LLC24$453
Pharmacyclics LLC, An Abbvie Company20$390
Johnson & Johnson23$390
Amgen30$371
Sanofi-aventis U.S. LLC4$356
E.r. Squibb & Sons, L.L.C.20$343
Astellas Pharma US Inc11$342
Gilead(2 entities)16$338
AbbVie17$332
Incyte Corporation15$275
Sanofi15$239
Bristol Myers Squibb13$227
Karyopharm Therapeutics Inc.13$216
Adaptive Biotechnologies Corporation13$212
Servier Pharmaceuticals LLC10$194
Exelixis Inc.5$164
Regeneron Healthcare Solutions, Inc.10$160
Takeda Pharmaceuticals U.S.A., Inc.9$157
Tersera Therapeutics LLC6$138
Genentech USA, Inc.9$137
Recordati_rare_diseases_inc.3$124
Jazz Pharmaceuticals Inc.7$124
Octapharma USA, Inc.5$117
GSK7$110
Ipsen Biopharmaceuticals, Inc4$96
Bayer5$90
Taiho Oncology, Inc.5$86
Pharmaessentia USA Corporation5$85
Array Biopharma Inc6$84
Syndax Pharmaceuticals, Inc.4$72
Mirati Therapeutics, Inc.4$70
Stemline Therapeutics Inc.3$52
Foundation Medicine, Inc.3$50
Tolmar Pharmaceuticals, Inc.2$32
Pharmaand GmbH2$29
Tolmar, Inc.2$29
Sobi, Inc1$25
Rigel Pharmaceuticals, Inc.2$23
Deciphera Pharmaceuticals Inc.1$19
Novocure Inc.1$19
Aimmune Therapeutics, Inc.1$19
Clovis Oncology, Inc.1$17
CTI Biopharma Corp.1$16
G1 Therapeutics, Inc.1$15
Blueprint Medicines Corporation1$15
Puma Biotechnology, Inc.1$15
Fennec Pharmaceuticals, Inc.1$14
Medtronic1$13
AMAG Pharmaceuticals, Inc.1$13
Blue Earth Diagnostics1$13
Boehringer Ingelheim1$13
Myriad Genetic Laboratories, Inc.1$12
Morphosys, US Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,859 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$72,393
Medicare patients
311
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Letrozole90$1,097
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$797
Ondansetron Hcl37$371
Prochlorperazine Maleate18$247
Acyclovir22$237
Potassium Chloride23$200
Levothyroxine Sodium32$188
Anastrozole13$180
Dexamethasone18$172
Escitalopram Oxalate17$138
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$134
Prednisone15$119
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$111
Montelukast Sodium16$104
Gabapentin14$82

Paid to pharmacies, not to this prescriber.

Other family in Hastings

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →